title: Infectious complications after autologous CD34-selected peripheral blood stem cell transplantation.
abstract: CD34 selection of peripheral hematopoietic blood stem cell products has been applied to reduce the risk of relapse after an autologous transplantation. However, CD34 selection is also associated with a significant reduction in T-cells, natural killer cells, and monocytes, and these reductions may influence immune reconstitution and thus increase the risk for infections. An increased incidence of cytomegalovirus (CMV) disease in patients receiving CD34-selected transplants has been reported. In this study, the incidence rate of infections other than CMV is reported in 32 patients who underwent myeloablative therapy followed by the infusion of CD34-selected autologous peripheral blood stem cells (PBSC) and compared to the rate in a contemporaneous group of 273 patients who received unselected autologous PBSC during the same time period. Infection surveillance and prevention strategies were identical between the 2 groups. More non-CMV infections occurred in the recipients of CD34-selected PBSC than in recipients of unselected PBSC (78% versus 30%, P < .0001). The differences in the rates of viral infections were mainly due to dermatomal and disseminated varicella-zoster virus (VZV) (any VZV, 26% versus 4%, P = .002; disseminated VZV, 11% versus 0.3%, P = .03) and parainfluenza 3 virus infections (13% versus 3%, P = .04). Bacterial infections were also more common among CD34-selected PBSC transplant recipients (34% versus 16%, P = .01), whereas fungal infections were not significantly different between the groups. In multivariable logistic regression models, the effect of CD34 selection on infection risk remained significant for viral infections and overall non-CMV infections. Infection-related mortality was not significantly different between the groups. In conclusion, the incidence of viral and bacterial infections appears to be increased in recipients of CD34-selected autologous PBSC transplants. Because the risk for infections approaches that seen in allogeneic transplant recipients, infection surveillance, diagnostic work-up, and prevention strategies similar to those used in allogeneic recipients are warranted.
authors.affiliation: Fred Hutchinson Cancer Research Center, Seattle Washington 98109-1024, USA.
authors.forename: Fulvio
authors.initials: F
authors.lastname: Crippa
authors.forename: Leona
authors.initials: L
authors.lastname: Holmberg
authors.forename: Rachel A
authors.initials: RA
authors.lastname: Carter
authors.forename: Heather
authors.initials: H
authors.lastname: Hooper
authors.forename: Kieren A
authors.initials: KA
authors.lastname: Marr
authors.forename: William
authors.initials: W
authors.lastname: Bensinger
authors.forename: Thomas
authors.initials: T
authors.lastname: Chauncey
authors.forename: Lawrence
authors.initials: L
authors.lastname: Corey
authors.forename: Michael
authors.initials: M
authors.lastname: Boeckh
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D018952:Antigens, CD34; D002648:Child; D003586:Cytomegalovirus Infections / Q000209:etiology / Q000517:prevention & control; D005260:Female; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications / Q000628:therapy; D009894:Opportunistic Infections / Q000209:etiology* / Q000382:microbiology / Q000517:prevention & control; D036102:Peripheral Blood Stem Cell Transplantation / Q000009:adverse effects* / Q000379:methods / Q000401:mortality; D012307:Risk Factors; D016019:Survival Analysis; D014182:Transplantation, Autologous / Q000009:adverse effects / Q000379:methods / Q000401:mortality
chemical_list: D018952:Antigens, CD34